Category: News

NewsAFR

Viomedo: Studie zur Bewertung der Wirksamkeit und Sicherheit des „Atrial Flow Regulators“ bei Patienten mit Lungenhochdruck (PROPHET-Studie)

Read more

Read More
NewsPFO

New Guideline Recommendations US and Germany

Stroke experts around the globe formulate demands for updated stroke guidelines in favor of PFO closure.

Read More
NewsASDPFO

Die Helfer des Herzens

Interview mit Tor Peters, CEO Occlutech

Read More
NewsPFO

Ein Schirmchen schützt vor einem Schlaganfall

Stader Tagesblatt, April 22 2018 (German)

A PFO Success-Story: 0 to 28 since November 2017

Read More
NewsPmVSD

Occlutech obtains European CE Mark for its novel PmVSD Occluder

Schaffhausen, Switzerland – Occlutech, a leading innovator of implants to treat structural heart disease, today announced that it has obtained European CE Mark approval for its Perimembranous Ventricular Septal Defect (PmVSD) Occluder. The device is a specifically designed implant indicated for the minimally invasive closure of perimembranous ventricular septal defects…

Read More
News

Occlutech obtains European CE mark approval for its LAA Occluder

Schaffhausen, Switzerland -Occlutech, a leading innovator of implants to treat structural heart disease,today announced that it has obtained European CE Mark approval for its Left Atrial Appendix, (LAA), occluder. The device is a specifically designed implant for theminimally invasive closure of the LAA, a procedure that minimizes the risk of strokes in patients suffering from atrial fibrillation…

Read More
News

Occlutech awarded by Frost & Sullivan

Frost & Sullivan Applauds Occlutech’s Commitment to Customer-focused Innovation and a Broad Product Range of Minimally-invasive Structural Heart Devices…

Read More
NewsPLD

Early experience of percutaneous paravalvular leak closure using a novel Occlutech occluder

Paravalvular regurgitation is an important complication of mitral valve replacement. Although surgical repair is mostly recommended, it is associated with significant morbidity. On the other hand, percutaneous closure is a less invasive alternative approach…

Read More
NewsASD

Occlutech obtains Japanese MHW Approval for its ASD Closure Device

Schaffhausen, Switzerland – Occlutech, a leading innovator of implants to treat structural heart disease today announced that it has obtained Japanese MHW approval for its dedicated Atrial Septal Defect Closure Device. The device is a specifically designed implant indicated for the minimally invasive closure of Atrial Septal Defects, ASD…

Read More
NewsmVSD

Occlutech obtains European CE Approval for its novel mVSD Device

Schaffhausen, Switzerland – Occlutech, a leading innovator of implants to treat structural heart disease today announced that it has obtained European CE Mark approval for its dedicated muscular Ventricle Septal Defect Closure Device, (VSD). The device is a specifically designed implant indicated for the minimally invasive closure of muscular Ventricle Septal Defects, VSD…

Read More

We use cookies to customize content for your viewing and for analytics. If you continue to browse this website, we will assume that you are happy to receive all our cookies. Learn more